Extract
Inhaled corticosteroid/formoterol (ICS/FOR) combination medications were initially developed as maintenance therapy; more recently they are also used as relievers in Europe and this use is proposed in the USA. ICS coupled with FOR (a long-acting β2-agonist) is recommended by the 2020 Global Initiative for Asthma (GINA) guidelines [1] for steps 2–5 as maintenance and reliever (SMART) and is recommended for steps 3 and 4 in the 2020 USA National Asthma Education and Prevention Program (NAEPP) [2]. While SMART has regulatory approval in Europe, it does not in the USA.
Abstract
Prescribers and asthma patients should know that ICS/LABA combination inhalers used as reliever therapy may expire under patient use sooner than the expiration shown on the inhaler, compromising effectiveness if not considered by the prescriber and patient https://bit.ly/3fhHMX2
Footnotes
Conflict of interest: R.A Pleasants reports grants and personal fees from Boehringer Ingelheim and Teva, personal fees from AstraZeneca, Theravance and Grifols, during the conduct of the study.
Conflict of interest: S.L. Tilley has nothing to disclose.
Conflict of interest: A.J. Hickey has nothing to disclose.
Conflict of interest: O.S. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, grants from Edmond Pharma, personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, Covis, Novartis, Mereo Biopharma, Orion, Menarini, UCB and Trudell Medical, outside the submitted work.
- Received October 20, 2020.
- Accepted November 16, 2020.
- Copyright ©ERS 2021
LIBRARY USERS
Log in through your institution
Purchase access
